CNBX Pharmaceuticals (CNBX) Equity Ratio (2016 - 2025)
CNBX Pharmaceuticals (CNBX) has disclosed Equity Ratio for 13 consecutive years, with 230.51 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Ratio fell 104.52% year-over-year to 230.51, compared with a TTM value of 230.51 through Nov 2025, down 104.52%, and an annual FY2025 reading of 135.4, down 71.34% over the prior year.
- Equity Ratio was 230.51 for Q4 2025 at CNBX Pharmaceuticals, down from 135.4 in the prior quarter.
- Across five years, Equity Ratio topped out at 2.01 in Q3 2022 and bottomed at 230.51 in Q4 2025.
- Average Equity Ratio over 5 years is 40.36, with a median of 4.2 recorded in 2023.
- The sharpest move saw Equity Ratio soared 243.08% in 2022, then plummeted 1984.27% in 2024.
- Year by year, Equity Ratio stood at 0.38 in 2021, then crashed by 955.55% to 3.24 in 2022, then crashed by 66.95% to 5.41 in 2023, then tumbled by 1984.27% to 112.71 in 2024, then crashed by 104.52% to 230.51 in 2025.
- Business Quant data shows Equity Ratio for CNBX at 230.51 in Q4 2025, 135.4 in Q3 2025, and 136.31 in Q2 2025.